Compare DexCom, Inc. (DXCM) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lamb Weston Holdings Inc — how do they compare? DexCom, Inc. trades at $76.89 (market cap $28.06B), while Lamb Weston Holdings Inc trades at $47.04 (market cap $6.29B). The key difference: DexCom, Inc. is far larger — about 4.5× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 3.34% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | LW | |
|---|---|---|
Market Cap | $28.06B | $6.29B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $66.57 |
52-Week Low | $54.84 | $38.48 |
Enterprise Value | $27.03B | $10.25B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Lamb Weston (LW) trades at $46.74, up 0.52% today, near the analyst consensus price target of $49.33. The stock shows a neutral technical stance with support at $45 and resistance at $47. Recent quarters have consistently beaten EPS estimates, with Q2 2026 results expected soon. Revenue remains stable at $6.45B in 2025, though net income declined to $357M. The company's 'Focus to Win' strategy is gaining traction, supported by cost savings and volume growth in North America.
Outlook is cautiously optimistic with potential upside to price targets, but risks include margin pressure, a pending class action lawsuit, and high debt levels. Analyst sentiment is mixed with 35% buy ratings. Earnings on July 24, 2026, will be critical for confirming the turnaround narrative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
